Sun Pharmaceutical had sought grant of 'emergency authorisation status' to its plant-based drug, ACQH, which is being developed as a potential treatment for dengue.
Sun Pharma said human safety study of AQCH already completed, clinical trials will be conducted across 12 centres on 210 patients. The treatment duration will be 10 days.
The Mumbai-based drug-maker has submitted a proposal to the govt to conduct Phase II clinical trials of the drug to see if it can treat patients suffering from Covid-19.
The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
CSE, one of India’s oldest bourses, is edging towards a voluntary exit. It could never recover from market manipulation scam that caused a payment crisis at exchange back in 2001.
Fresh details of operation conducted by IAF, Army have come out in gazette notification giving citations of those who were awarded Vir Chakra for their bravery.
Education, reservations, govt jobs are meant to bring equality and dignity. That we are a long way from that is evident in the shoe thrown at the CJI and the suicide of Haryana IPS officer. The film Homebound has a lesson too.
COMMENTS